Alfred Jenkins, MD
Gynecologic Oncology · Tulsa, OKNPI 1487686200
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $765 of the $994 with a category attached, or 76.9%. 14 manufacturers reported payments, led by AstraZeneca at 26.3% of the total. Reporting peaked in 2024 at $431 and has fallen 83.7% since, to $70 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in OK, where the typical reported total is $3,072.
Across 29 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$262
- Coloplast$239
- Genmab U.S., Inc.$143
- Novartis$65
- Astellas Pharma US Inc$45
- Tesaro, Inc.$41
- plus $200 from 8 others
What the payments were for
- Food & beverage$76577%
- Education$23023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 5 | $262 |
| Coloplast | 1 | $239 |
| Genmab U.S., Inc. | 2 | $143 |
| Novartis | 3 | $65 |
| Astellas Pharma US Inc | 2 | $45 |
| Tesaro, Inc. | 2 | $41 |
| Bristol Myers Squibb | 3 | $37 |
| GSK | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Pfizer | 2 | $33 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Merck | 1 | $17 |
| AbbVie | 1 | $13 |
| Clovis Oncology, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$994 in reported general payments places this provider in the 30th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 16 | $283,977 |
| EliquisApixaban | 12 | $6,708 |
| Prochlorperazine Maleate | 63 | $651 |
| Letrozole | 23 | $607 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 52 | $554 |
| Oxycodone Hcl | 36 | $401 |
| Ondansetron Hcl | 44 | $385 |
| Raloxifene Hcl | 11 | $340 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $250 |
| Levofloxacin | 42 | $242 |
| Gabapentin | 16 | $229 |
| Dexamethasone | 13 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $35 | $283,97716 claims |
| PfizerEliquis | $33 | $6,70812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 21 gynecologic oncology providers in Oklahoma.
Other gynecologic oncology in Tulsa
- Daron StreetTulsa$55K
- Katherine MoxleyTulsa$44K
- Michael GoldTulsa$15K
- Debra RichardsonOklahoma City$97K
- Camille JacksonOklahoma City$35K
- Tara CastellanoOklahoma City$26K
- Joan WalkerOklahoma City$11K
- Christina WashingtonOklahoma City$9K
- Roger PfeifferOwasso$7K
- Elizabeth EvansOklahoma City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.